期刊文献+

白细胞介素-10在慢性阻塞性肺病检测中的意义 被引量:2

Clinical Significance of IL-10 in Patients with COPD
暂未订购
导出
摘要 目的探讨白细胞介素-10(IL-10)、Ig、C3、C4与慢性阻塞性肺病(COPD)的关系及临床意义。方法选择20例COPD患者为观察组,20例健康老年人作正常对照。①采用双抗体夹心ELISA(生物素扩大)法,测定各例血清IL-10浓度。②采用散射比浊法测定各例血清Ig、C3、C4含量。结果20例健康老年人血清IL-10的含量为(11.49±4.24)Pg/mL、IgG(11.3±2.21)g/L、IgA(1.9±0.7)g/L、IgM(1.4±0.36)g/L、C3(1.2±0.22)g/L、C4(0.3±0.09)g/L。20例COPD患者血清IL-10含量为(63.18±48.35)Pg/m l、IgG(12.5±3.56)g/L、IgA(3.1±1.32)g/L、IgM(2.6±0.94)g/L、C3(1.6±0.5)g/L、C4(0.5±0.14)g/L。结论COPD患者的IL-10、IgA、IgM、C3、C4、与健康老年人相比差异有显著性(P<0.001),提示IL-10参与了COPD的发病机制和体液免疫调节,血清IL-10检测是COPD病情监测和疗效判断的较好指标。 Objective To investigate the relationship between the serum level of intedeukin -10 (IL- 10) ,Ig,C3,C4 and chronic obstructive pulmonary disease(COPD). Methods Choose 20 patients with COPD while 20 healthy elders were controls. ① The serum concentrations of IL - 10 were assayed by enzyme linked immunosorbent assay (ELISA). ② The serum concentrations of Ig, C3,C4 were assayed by nephelometry. Results The mean concentration of the eases was(63.18 ± 48. 35) Pg/ml,IgG( 11.3 ±2. 21 ) g/L,IgA ( 1.9 ±0. 7)g/L, IgM( 1.4 ±0. 36)g/L, C3 ( 1.2 ±0. 22) g/L, C4 (0. 3 ± 0. 09 ) g/L, while the controls was ( 11.49 ± 4. 24 ) Pg/ml, IgG ( 12. 5 ± 3.56 ) g/L, IgA (3.1 ±1.32)g/L,IgM(2. 6±0. 94)g/L,C3 (1.6 ±0. 5)g/L,C4(0. 5 ±0. 14) g/L. Conclusion The serum level of IL -10, IgA, IgM, C3, C4 in patients was different significantly from that of the controis (P 〈 0. 001) ,suggesting that IL- 10 was involved in the pathological development of COPD, and the serum level of IL- 10 was an appropriate index to evaluate COPD ,and the effect of treatment.
出处 《医药论坛杂志》 2006年第24期19-20,共2页 Journal of Medical Forum
关键词 白细胞介素-10 慢性阻塞性肺病 免疫球蛋白 C3 CA Interleukin - 10 Chronic obstructive pulmonary disease Ig C3 CA
  • 相关文献

参考文献4

二级参考文献23

  • 1Mallat Z, Heymes C, Ohan J, et al. [J]. Arterioscler Thromb Vasc Biol, 1999,19(3) :611-616.
  • 2Mallat Z, Bernard S, Duriez M, et al. [J]. Cite Res, 1999,85(8):17-24..
  • 3Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, et al. [J]. Cantiovasc Bes, 2001,49(4) :882-890.
  • 4Frangogiannis NG, Meadoza LH, Lindsey ML, et al. [J]. J Immunol,2000,165(5) : 2798-2808.
  • 5Yang Z, Zingarelli B, Szabo C. [ J ]. Circulation, 2000, 101 (9) :1019-1026.
  • 6Jones SP, Trocha SD, Lefer DJ. [J]. Am J Physiol Heart Circ Physiol,2001,281( 1 ) :48-52.
  • 7Yang Z, Szabo C. [J]. Shock, 2001,15(1) :77-79.
  • 8Nishio R, Matsumori A, Shioi T, et al. [J]. Circulation, 1999,100(10) : 1102-1108.
  • 9Nakano A, Matsumori A, Kawamoto S, et al. [J]. Hum Gene Ther,2001,12(10) : 1289-1297.
  • 10Watanabe K, Nakazawa M, Fuse K, et al. [J]. Circulation, 2001,104(10) : 1098-1100.

共引文献14

同被引文献20

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部